Literature DB >> 19209179

Cerebral haemodynamic response or excitability is not affected by sildenafil.

Christina Kruuse1, Adam E Hansen, Henrik B W Larsson, Martin Lauritzen, Egill Rostrup.   

Abstract

Sildenafil (Viagra), a cyclic guanosine monophosphate-degrading phosphodiesterase 5 inhibitor, induces headache and migraine. Such headache induction may be caused by an increased neuronal excitability, as no concurrent effect on cerebral arteries is found. In 13 healthy females (23+/-3 years, 70.3+/-6.6 kg), the effect of sildenafil on a visual (reversing checkerboard) and a hypercapnic (6% CO2 inhalation) response was evaluated using functional magnetic resonance imaging (fMRI, 3 T MR scanner). On separate occasions, visual-evoked potential (VEP) measurements (latency (P100) and maximal amplitude) were performed. The measurements were applied at baseline and at both 1 and 2 h after ingestion of 100 mg of sildenafil. Blood pressure, heart rate and side effects, including headache, were obtained. Headache was induced in all but one subject on both study days. Sildenafil did not affect VEP amplitude or latency (P100). The fMRI response to visual stimulation or hypercapnia was unchanged by sildenafil. In conclusion, sildenafil induces mild headache without potentiating a neuronal or local cerebrovascular visual response or a global cerebrovascular hypercapnic response. The implication is that sildenafil-induced headache does not include a general lowering of threshold for a neuronal or cerebrovascular response, and that sildenafil does not modulate the hypercapnic response in healthy subjects.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19209179     DOI: 10.1038/jcbfm.2009.10

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  10 in total

1.  Effects of Sildenafil on Cerebrovascular Reactivity in Patients with Becker Muscular Dystrophy.

Authors:  Ulrich Lindberg; Nanna Witting; Stine Lundgaard Jørgensen; John Vissing; Egill Rostrup; Henrik Bo Wiberg Larsson; Christina Kruuse
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

Review 2.  An update on the blood vessel in migraine.

Authors:  K C Brennan; Andrew Charles
Journal:  Curr Opin Neurol       Date:  2010-06       Impact factor: 5.710

3.  Sildenafil Improves Vascular and Metabolic Function in Patients with Alzheimer's Disease.

Authors:  Min Sheng; Hanzhang Lu; Peiying Liu; Yang Li; Harshan Ravi; Shin-Lei Peng; Ramon Diaz-Arrastia; Michael D Devous; Kyle B Womack
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

4.  Effect of hypoxia on BOLD fMRI response and total cerebral blood flow in migraine with aura patients.

Authors:  Nanna Arngrim; Anders Hougaard; Henrik W Schytz; Mark B Vestergaard; Josefine Britze; Faisal Mohammad Amin; Karsten S Olsen; Henrik Bw Larsson; Jes Olesen; Messoud Ashina
Journal:  J Cereb Blood Flow Metab       Date:  2017-07-07       Impact factor: 6.200

5.  Effects of daily low-dose treatment with phosphodiesterase type 5 inhibitor on cognition, depression, somatization and erectile function in patients with erectile dysfunction: a double-blind, placebo-controlled study.

Authors:  Y S Shim; C-U Pae; K J Cho; S W Kim; J C Kim; J S Koh
Journal:  Int J Impot Res       Date:  2013-11-28       Impact factor: 2.896

6.  Defining the phosphodiesterase superfamily members in rat brain microvessels.

Authors:  Zhen He; Li Cui; Tucker A Patterson; Merle G Paule
Journal:  ACS Chem Neurosci       Date:  2011-06-27       Impact factor: 4.418

Review 7.  Development of novel phosphodiesterase 5 inhibitors for the therapy of Alzheimer's disease.

Authors:  Elisa Zuccarello; Erica Acquarone; Elisa Calcagno; Elentina K Argyrousi; Shi-Xian Deng; Donald W Landry; Ottavio Arancio; Jole Fiorito
Journal:  Biochem Pharmacol       Date:  2020-01-21       Impact factor: 5.858

Review 8.  Phosphodiesterases as therapeutic targets for Alzheimer's disease.

Authors:  Ana García-Osta; Mar Cuadrado-Tejedor; Carolina García-Barroso; Julen Oyarzábal; Rafael Franco
Journal:  ACS Chem Neurosci       Date:  2012-10-01       Impact factor: 4.418

9.  The effect of phosphodiesterase-5 inhibitors on cerebral blood flow in humans: A systematic review.

Authors:  Mathilde Mh Pauls; Barry Moynihan; Thomas R Barrick; Christina Kruuse; Jeremy B Madigan; Atticus H Hainsworth; Jeremy D Isaacs
Journal:  J Cereb Blood Flow Metab       Date:  2017-12-19       Impact factor: 6.200

10.  Effects of sildenafil and calcitonin gene-related peptide on brainstem glutamate levels: a pharmacological proton magnetic resonance spectroscopy study at 3.0 T.

Authors:  Samaira Younis; Anders Hougaard; Casper Emil Christensen; Mark Bitsch Vestergaard; Esben Thade Petersen; Olaf Bjarne Paulson; Henrik Bo Wiberg Larsson; Messoud Ashina
Journal:  J Headache Pain       Date:  2018-06-18       Impact factor: 7.277

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.